Abstract
Despite almost a century of efforts in the treatment of brain arteriovenous malformations (BAVMs) no clinical trial has yet been performed to demonstrate the benefits of intervention versus conservative (medical) management for those not yet bled. Only insufficient information on the natural history of unbled BAVMs exists to certify that intervention is needed and that such intervention produces a better long-term functional outcome.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Achrol AS, Pawlikowska L, McCulloch CE, Poon KY, Ha C, Zaroff JG, Johnston SC, Lee C, Lawton MT, Sidney S, Marchuk DA, Kwok PY, Young WL, UCSF BAVM Study Project (2006) Tumor necrosis factor-alpha-238G > A promoter polymorphism is associated with increased risk of new hemorrhage in the natural course of patients with brain arteriovenous malformations. Stroke 37: 231–234
Berman MF, Hartmann A, Mast H, Sciacca RR, Mohr JP, Pile-Spellman J, Young WL (1999) Determinants of resource utilization in the treatment of brain arteriovenous malformations. Am J Neuroradiol 20: 2004–2008
Castel JP, Kantor G (2001) Postoperative morbidity and mortality after microsurgical exclusion of cerebral arteriovenous malformations. Current data and analysis of recent literature. Neurochirurgie 47: 369–383
Chen Y, Fan Y, Poon KY, Achrol AS, Lawton MT, Zhu Y, McCulloch CE, Hashimoto T, Lee C, Barbaro NM, Bollen AW, Yang GY, Young WL (2006) MMP-9 expression is associated with leukocytic but not endothelial markers in brain arteriovenous malformations. Front Biosci 11: 3121–3128
Chen Y, Pawlikowska L, Yao JS, Shen F, Zhai W, Achrol AS, Lawton MT, Kwok PY, Yang GY, Young WL (2006) Interleukin-6 involvement in brain arteriovenous malformations. Ann Neurol 59: 72–80
Choi JMJ, Sciacca RR, Hartmann A, Khaw AV, Mast H, Sacco RL, Stapf C (2006) Clinical outcome after first and subsequent hemorrhage in patients with untreated brain Arteriovenous malformations. Stroke (in press)
Choi JH, Mast H, Sciacca RR, Hartmann A, Khaw AV, Mohr JP, Sacco RL, Stapf C (2006) Clinical outcome after first and recurrent hemorrhage in patients with untreated brain arteriovenous malformation. Stroke 37: 1243–1247
Choi JH, Mohr JP (2005) Brain arteriovenous malformations in adults. Review. Lancet Neurol 4: 299–308
Hartmann A, Mast H, Mohr JP, Koennecke HC, Osipov A, Pile-Spellman J, Duong DH, Young WL (1998) Morbidity of intracranial hemorrhage in patients with cerebral arteriovenous malformation. Stroke 29: 2001–2002
Hartmann A, Mast H, Mohr JP, Pil-Spellman J, Connolly ES, Sciacca RR, Khaw A, Stapf C (2005) Determinants of staged endovascular and surgical treatment outcome of brain arteriovenous malformations. Stroke 36: 2431–2435
Hartmann A, Pile-Spellman J, Stapf C, Sciacca RR, Faulstich A, Moor JP, Schumacher HC, Mast H (2002) Risk of endovascular treatment of brain arteriovenous malformations. Stroke 33: 1816–1820
Hashimoto T, Matsumoto MM, Li JF, Lawton MT, Young WL, University of California, San Francisco, BAVM Study Group (2005) Suppression of MMP-9 by doxycycline in brain arteriovenous malformations. BMC Neurol 5: 1
Haw CS, terBrugge K, Willinsky R, Tomlinson G (2006) Complications of embolization of arteriovenous malformations of the brain. J Neurosurg 104: 226–232
Hillman J (2001) Population-based analysis of arteriovenous malformation treatment. J Neurosurg 95: 633–637
Lawton MT, Du R, Tran MN, Achrol AS, McCulloch CE, Johnston SC, Quinnine NJ, Young WL (2005) Effect of presenting hemorrhage on outcome after microsurgical resection of brain arteriovenous malformations. Neurosurgery 56: 485–493
Mast H, Young WL, Koennecke HC, Sciacca RR, Osipov A, Pile-Spellman J, Hacein-Bey L, Duong H, Stein BM, Mohr JP (1997) Risk of spontaneous haemorrhage after diagnosis of cerebral arteriovenous malformation. Lancet 350: 1065–1068
Ondra SL, Troupp H, George ED, Schwab K (1990) The natural history of symptomatic arteriovenous malformations of the brain: a 24-year follow-up assessment. J Neurosurg 73: 387–391
Stapf C, Mast H, Sciacca RR, Berenstein A, Nelson PK, Gobin YP, Pile-Spellman J, Mohr JP, New York Islands Study Collaborators (2003) The New York Islands AVM Study: design, study progress, and initial results. Stroke 34: e29–e33
Stapf C, Mast H, Sciacca RR, Choi JH, Khaw AV, Connolly ES, Pile-Spellman J, Mohr JP (2006) Predictors of hemorrhage in patients with untreated brain arteriovenous malformation. Neurology 66: 1350–1355
Stapf C, Mohr JP, Choi JH, Hartmann A, Mast H (2006) Invasive treatment of unruptured brain arteriovenous malformations is experimental therapy. Curr Opin Neurol 19: 63–68
Sure U, Butz N, Siegel AM, Mennel HD, Bien S, Bertalanffy H (2001) Treatment-induced neoangiogenesis in cerebral arteriovenous malformations. Clin Neurol Neurosurg 103: 29–32
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag
About this paper
Cite this paper
Mohr, J.P. (2008). A randomized trial of unruptured brain arteriovenous malformations (ARUBA). In: Yonekawa, Y., Tsukahara, T., Valavanis, A., Khan, N. (eds) Changing Aspects in Stroke Surgery: Aneurysms, Dissections, Moyamoya Angiopathy and EC-IC Bypass. Acta Neurochirurgica Supplements, vol 103. Springer, Vienna. https://doi.org/10.1007/978-3-211-76589-0_1
Download citation
DOI: https://doi.org/10.1007/978-3-211-76589-0_1
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-76588-3
Online ISBN: 978-3-211-76589-0
eBook Packages: MedicineMedicine (R0)